Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
CC transcript
Appointed director
Quarterly results
|
|
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| Vakiener Victoria (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 1,550 shares
@ $26.33, valued at
$40.8k
|
|
| 09/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/07/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/06/2023 |
4
| Oliver Tracie (Chief Commercial Officer) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 8,925 shares
@ $35.31, valued at
$315.1k
|
|
| 07/05/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 3,000 shares
@ $35.53, valued at
$106.6k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/29/2023 |
4
| Myszkowski Kenneth Allen (CFO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 15,000 shares
@ $36.2, valued at
$543k
|
|
| 06/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.1% stake in Arrowhead Pharmaceuticals Inc. |
| 05/08/2023 |
4
| GIVEN DOUGLAS B (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 6,500 shares
@ $40.9, valued at
$265.9k
|
|
| 05/05/2023 |
4
| Anzalone Christopher Richard (CEO) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 54,928 shares
@ $39.14, valued at
$2.1M
Sold 24,008 shares
@ $38.97, valued at
$935.6k
Sold 25,992 shares
@ $40.02, valued at
$1M
Exercised 54,928 options to buy
@ $2.01, valued at
$110.4k
Exercised 50,000 options to buy
@ $2.01, valued at
$100.5k
|
|
| 05/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/02/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/20/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 03/06/2023 |
4
| OLUKOTUN ADEOYE Y (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 11,350 shares
@ $32.65, valued at
$370.6k
|
|
| 03/01/2023 |
4
| GIVEN DOUGLAS B (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 875 shares
@ $32.62, valued at
$28.5k
|
|
| 02/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.7% stake in Arrowhead Pharmaceuticals Inc. |
| 02/08/2023 |
SC 13G/A
| STATE STREET CORP reports a 5.6% stake in AMENDED FILING ARROWHEAD PHARMACEUTICALS INC |
| 02/06/2023 |
8-K
| Quarterly results |
| 02/06/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/30/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 01/30/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 12% stake in ARROWHEAD PHARMACEUTICALS INC |
| 01/20/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 01/20/2023 |
SC 13G
| BlackRock Inc. reports a 12% stake in ARROWHEAD PHARMACEUTICALS INC |
| 01/12/2023 |
4
| Ferrari Mauro (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| De Backer Marianne (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| Vakiener Victoria (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 1,764 shares
@ $0
Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| PERRY MICHAEL S (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
| 01/11/2023 |
4
| GIVEN DOUGLAS B (Director) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 7,867 shares
@ $0
Granted 4,593 options to buy
@ $33.03, valued at
$151.7k
|
|
|
|
|